Preclinical NHP data claims ~5 / 4 / 4 greater potency than retatrutide at GLP-1R / GIPR / GCGR, with ~1-month injection durability
While earlier studies suggested a possible modest increase in risk, more recent comprehensive analyses have found no significant association after adjusting for confounding factors such as obesity, diabetes duration, and concurrent medications
Immediate medical attention is required if taste changes are accompanied by: Severe, persistent vomiting preventing adequate fluid intake Signs of dehydration (dark urine, dizziness, decreased urination) Severe abdominal pain, particularly if persistent or worsening Symptoms of pancreatitis (severe upper abdominal pain radiating to the back, nausea, vomiting) Right upper quadrant pain, fever, or yellowing of skin/eyes (possible gallbladder disease) Symptoms of hypoglycemia (if also taking insulin or sulfonylureas): shakiness, sweating, confusion, irritability These symptoms may indicate serious adverse effects requiring urgent evaluation, including pancreatitis, gallbladder disease, gastroparesis, or severe dehydration
A.KleerebezemM
/assets/images/provider/photos/2775905.jpeg)
